Basic Information Experimental Physicochemical Property Pharmacokinetic/Toxicokinetic Property Maximum Dosage Drug Property Radar Chart

Basic Information

Drug ID DDPD00912 ...
Drug Name Repaglinide
Molecular Weight 452.5857
Molecular Formula C27H36N2O4
CAS Number 135062-02-1
SMILES CCOC1=C(C=CC(CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N2CCCCC2)=C1)C(O)=O
External Links
DRUGBANK DB00912
PubChem Compound 65981
PDR 1005
Drugs.com Drugs.com Drug Page

Experimental Physicochemical Property

Property Name Property Value Unit Raw Value Raw Unit Reference
Log P 5.9 - 5.9 - DRUGBANK
Melting Point 130.5 ℃ 130-131 ℃ DRUGBANK

Pharmacokinetic/ Toxicokinetic Property

Property Name Property Value Unit Raw Value Raw Unit Annotation Factor Reference
Absorption 100.0 % 100 % PO, oral; DRUGBANK
AUC 18.4 ng.h/ml 18.0-18.7 ng.h/ml Oral single dose; DRUGBANK
Bioavailability 56.0 % 56 % PO, oral; DRUGBANK
Bioavailability 56.0 % 56±7 % PO, oral; Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
C Max 47.0 ng/ml 47±24 ng/ml Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
T Max 1.0 h 1(0.5-1.4) h PO, oral; DRUGBANK
T Max 0.50 h 0.25-0.75 h Male, men; adults; normal,healthy; The Pharmacological Basis of Therapeutics
Clearance 35.5 L/h 33-38 L/h intravenous injection, IV; DRUGBANK
Clearance 0.56 L/h/kg 9.3±6.8 ml/min/kg normal,healthy; adults; Male, men; hydrolysis; hepatopathy，LD ↓ ;RD, renal impairment, Renal disease，including uremia ↓ ; The Pharmacological Basis of Therapeutics
Clearance 0.47 L/h/kg 7.8 ml/min/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Volume of Distribution 31.0 L 31.0 L intravenous injection, IV; normal,healthy; DRUGBANK
Volume of Distribution 0.52 L/kg 0.52±0.17 L/kg normal,healthy; adults; Male, men; hydrolysis; The Pharmacological Basis of Therapeutics
Volume of Distribution 0.35 L/kg 0.35 L/kg intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Half-life 1.0 h 1 h DRUGBANK
Half-life 0.80 h 0.8±0.2 h normal,healthy; adults; Male, men; chronic liver disease ↑ ; The Pharmacological Basis of Therapeutics
Half-life 0.87 h 0.87 h intravenous injection, IV; human, homo sapiens; Human Intravenous Pharmacokinetic Dataset
Toxicity LD50 1000.0 mg/kg >1 g/kg Rattus, Rat; DRUGBANK
Eliminate Route 90.0 % 90 % Faeces excretion; DRUGBANK
Eliminate Route 80.0 % 8 % Urinary excretion; DRUGBANK
Eliminate Route 1.8 % <1.8 % Faeces excretion; Unchanged drug; DRUGBANK
Eliminate Route 0.008000 % 0.008 % Urinary excretion; Unchanged drug; DRUGBANK
Eliminate Route 1.5 % 0.3-2.6 % Urinary excretion; adults; Male, men; normal,healthy; human, homo sapiens; Unchanged drug; The Pharmacological Basis of Therapeutics
Protein Binding 98.0 % >98 % DRUGBANK
Protein Binding 97.4 % 97.4 % adults; Male, men; normal,healthy; human, homo sapiens; The Pharmacological Basis of Therapeutics

Maximum Dosage

Property Name Property Value Unit Raw Value Raw Unit Annotation Brand Name Component Reference
Max dose for adults 16.0 mg/day 16 mg/day PO, oral Prandin repaglinide PDR
Max dose for elderly 16.0 mg/day 16 mg/day PO, oral Prandin repaglinide PDR

Drug Property Radar Chart

...

Note: Center: Q1-1.5*IQR, Edge: Q3+1.5*IQR; Q1: Quantile 1, Q3: Quantile 3, IQR: Q3-Q1